Viewpoint Molecular Targeting, Inc. has been awarded a $300,000 Small Business Innovation Research (SBIR) Phase I Grant by the National Institutes of Health. This marks a total of over $3M in funding and a total of 7 awards by the NIH to Viewpoint. These awards help to develop our image guided therapy and diagnostics for metastatic melanoma. “These funds will accelerate our product development helping us bring our product forward into clinical trials.” said Viewpoint Biochemical Engineer Edwin Sagastume. Each award provides a vetting of the approach and technology by recognized experts that serve on NIH review committees. 

The NIH SBIR program funds early stage small businesses that are seeking to commercialize innovative biomedical technologies. This competitive program helps small business participate in federal research and development to develop life-saving technologies and create jobs. 

About the NIH SBIR Program

Viewpoint’s products are currently under development and therefore not approved by the FDA.